Myriad Genetics Acquires Counsyl, a Women’s Health Lab

Myriad Genetics Acquires Counsyl, a Women’s Health Lab

Myriad Genetics (NASDAQ: MYGN) agreed to pay $375 million to acquire privately held Counsyl, Inc., which operates a high-complexity clinical laboratory dedicated to women’s health. Counsyl’s lab services include carrier and non-invasive prenatal screening, including its Foresight Carrier Screen, Prelude Prenatal Screen, Reliant Cancer Screen, as well as supporting services through Counsyl Complete, a suite of solutions that integrate Counsyl screening into clinical workflows and patients’ lives. Since the company’s founding, Counsyl has championed key advances in screening for women and their families, screening more than 850,000 patients, serving more than 17,000... Read More »